Brent Sabatini - Oct 1, 2024 Form 3 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
SVP, Chief Accounting Officer
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
3
Date filed
10/2/2024, 12:09 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VIR Common Stock 28.4K Oct 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 30K $22.49 Direct F1
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 30K $10.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the stock option vested and became exercisable on February 13, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F2 1/4 of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.